A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Northwell Nurse Sandra Lindsay is 1st for Pfizer COVID Vaccine – Again

The first American to receive the COVID-19 vaccine in 2020 repeated the feat again today as part of a public health awareness event. Sandra Lindsay, RN, became a global phenomenon on December 14, 2020, when the Northwell Health critical care nurse director received the Pfizer-BioNTech COVID-19 vaccine.

Nearly three years later, Nurse Lindsay volunteered to be the first American to receive this season’s shot: Pfizer-BioNTech 2023-24 COVID-19 vaccine. This mRNA formulation offers protection against BA.2, BA.2.86 “Pirola,” EG.5 “Eris,” XBB.1.5 COVID variants – needed immunity as COVID hospitalizations begin to rise ahead of the fall and winter season.

Despite serving on the front lines of the pandemic, Nurse Lindsay has yet to be infected with COVID-19. “It’s important that people understand that COVID is still around and can still severely affect an individual,” said Nurse Lindsay. “Having worked through the darkest days of the pandemic and seen the devastating effects it can have, I tell people not to take chances. We have powerful weapons like vaccines to prevent those devastating outcomes.”

This was the third COVID-19 vaccine – and sixth, including boosters – taken by Nurse Lindsay, who has since been elevated to the role of vice president of public health advocacy at Northwell. The FDA approved Pfizer’s vaccine on Monday followed by the CDC’s Advisory Committee on Immunization Practices on Tuesday.

Michelle Chester, FNP-BC, DNP, senior director of Employee Health Services at Northwell, administered the shot. She also gave Nurse Lindsay the vaccine in 2020. Also joining Nurse Lindsay in receiving vaccinations were: Adam Berman, MD, associate chair of emergency medicine at Long Island Jewish Medical Center in New Hyde Park; Mozhdeh Mehrabian, a respiratory therapist at North Shore University Hospital in Manhasset; and Mangala Narasimhan, MD, senior vice president of critical care services at Northwell.

“Vaccination is and has proven to be an important tool to fight against the severity of COVID-19,” said Jill Kalman, MD, chief medical officer and deputy physician in chief at Northwell Health. “We’re here now to reinforce that there is extra protection available against the newest COVID-19 variants as the FDA and CDC have approved a new seasonal vaccine.”

Northwell has administered about 800,000 doses of COVID-19 vaccine since the end of 2020. The FDA and CDC have said the vaccine is safe and effective for anyone ages 6 months and older. Northwell Health will offer both Pfizer and Moderna vaccines to its employees and the general public through its ambulatory network once it receives doses.

“It’s been three-and-a-half years since COVID hit the world and we have not forgotten,” said Bruce Farber, MD, chief of public health and epidemiology at Northwell. “At the peak of the First Wave, our health system had nearly 3,500 hospitalized COVID patients. This week, it’s less than 200. Even though that number has bumped up considerable since July, the majority are incidental cases, meaning that they have been hospitalized for some other reason. Nevertheless, COVID causes at lot of morbidity and it interrupts lives. That’s why we support vaccines as a major way to prevent COVID.”

Dr. Farber also warned of a surge later this fall and into the winter – another possible “tripledemic” of COVID, flu and RSV – unless Americans embrace vaccines. Flu and COVID vaccines can be taken at the same time. RSV is also available and should be considered for at-risk populations.

Northwell Health is New York State’s largest health system and private employer.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Simpson Interventions is committed to collaborating closely with the FDA and other stakeholders to advance the development and regulatory review of the Acolyte Image Guided Crossing and Re-Entry Catheter System. The company looks forward to bringing this revolutionary technology to clinicians, and patients in need.
"The U.S. approval of TriClip is a significant advancement for people suffering from tricuspid regurgitation, a heart condition that negatively impacts their quality of life and puts them at grave risk of serious health issues," said Paul Sorajja, M.D., the Roger L. and Lynn C. Headrick Family Chair of the Valve Science Center for the Minneapolis Heart Institute Foundation and director of the Center for Valve and Structural Heart Disease for the Minneapolis Heart Institute at Abbott Northwestern Hospital and co-principal investigator of the TRILUMINATE™ Pivotal trial. "With TriClip, physicians can offer patients a therapy option backed by excellent safety and effectiveness to help restore tricuspid native valve performance without subjecting them to high-risk open-heart surgery that may not be feasible for individuals with TR who are generally older and sicker."
This make it one of the only wearable OTC anti-migraine device that is available without a prescription in the U.S.
NanoDrop has received clearance in the United States as the inaugural blood-lancing device available for over-the-counter use on the upper arm. This development is poised to revolutionize the consumer testing market and decentralized clinical trials within the realm of at-home healthcare.
"Receiving Fast Track designation is a significant milestone in addressing the high unmet medical need for PSC, and it will facilitate the efficient development of LB-P8 by enabling close communication with the regulatory authority," said Jiyoung Ahn, Head of Clinical Development, LISCure. "By having enhanced communication with the regulatory authority, we will expeditiously bring forward a novel therapy option in an area with limited available treatments."

By using this website you agree to accept Medical Device News Magazine Privacy Policy